Metronomic oral cyclophosphamide (MOC) therapy in the recurrent and advanced ovarian cancer patients: a retrospective study
Journal Title: IP International Journal of Medical Paediatrics and Oncology - Year 2017, Vol 3, Issue 2
Abstract
Introduction: To evaluate the efficacy of cycled oral cyclophosphamide therapy in recurrent and advanced ovarian cancer patients. Materials and Method: Recurrent and advanced ovarian cancer patients who are unfit for intensive chemotherapy were prescribed oral cyclophosphamide at the dose of 50 mg twice daily for 10 days, cycled every 28 days. Treatment-related toxicity was[N1] assessed by National cancer institute – common terminology criteria for adverse events(NCI-CTCAE) and response to treatment were assessed by Response evaluation criteria in solid tumours (RECIST) and clinical assessment. Progression-free (PFS), and overall survival (OS) were assessed using Kaplan meier survival analysis. Results: 71 patients of ovarian cancer admitted to our centre from January 2012 to March 2015 with mean age of 61.2±0.74 years were analyzed: 44 patients (61.9%) were platinum refractory/resistant, while 26 patients (36.6%) were platinum sensitive; 60 patients (84%) had received atleast one previous chemotherapy before starting MOC. The objective response rate (ORR) (complete and partial response) was 20%. Stable disease was seen in 22 patients (30.9%) and 17patients had response duration ≥6 months, 8 patients had continued response for more than 1 year. Progression during treatment was observed in 49 patients (69.01%). Median PFS was 5 months (range 2 – 25 months), and the 12-month PFS was 11%; and the 12-month OS was 26% Median PFS for patients who responded to MOC was 9 months whereas 2 months for those who progressed (p = 0.01). Median OS of responding patients was 14 months whereas it was 8 months for patients progressive on MOC (p = 0.02). No significant toxicity was observed. Conclusions: MOC is an effective therapy in the treatment of recurrent and advanced ovarian cancer patients, unfit for intensive chemotherapy.
Authors and Affiliations
V. Arun Ramanan, K. Kalaichelvi, S. Lakshminarasimhan
Keywords
Related Articles
- EP ID EP300713
- DOI 10.18231/2455-6793.2017.0013
- Views 100
- Downloads 0
Spindle Cell Carcinoma of the Tongue: A Case Report and Review of Literature
Spindle cell carcinoma (SpCC) or sarcomatoid carcinoma of the tongue is rare and aggressive variant of squamous cell carcinoma with incidence of <1%. It is characterised by proliferation of epithelial and mesenchymal com...
Study on dietary pattern and physical activity before diagnosis of cancer in cancer patients of a teaching hospital of Jharkhand: A pilot study
Introduction Cancer is among the leading causes of death worldwide It poses a major threat to public health worldwide and incidence has increased in most countries since 1990 The study aims to find any association betwee...
Comparative study of analgesic effect of breast feeding versus dextrose during heel lance in neonates
Aim: Firstly, to assess the level of pain in new-borns enrolled in the study, after heel lance. Secondly, to determine the effect of oral dextrose solution and breast feeding on procedural pain in new-borns in the experi...
Effect of peritoneal dialysis on malarial AKI children: a cross sectional study
Background: Peritoneal dialysis (PD) is the main stream of treatment as renal replacement therapy in pediatric patients with AKI in developing countries. Acute kidney injury (AKI) is a well-recognized complication of sev...
Complete Diphallia with no other associated congenital anomaly
We report a case of Diphallus in a term – appropriate for gestational age, male child weighing 3.1 kg with abnormal genitalia i.e. double penises one below the other with normal scrotum and normal sized testis. No other...